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OBJECTIVE—Several transcription factors are essential to pan-
creatic islet -cell development, proliferation, and activity, in-
cluding MafA and MafB. However, MafA and MafB are distinct
from others in regard to temporal and islet cell expression
pattern, with -cells affected by MafB only during development
and exclusively by MafA in the adult. Our aim was to deﬁne the
functional relationship between these closely related activators
to the -cell.
RESEARCH DESIGN AND METHODS—The distribution of
MafA and MafB in the -cell population was determined immu-
nohistochemically at various developmental and perinatal stages
in mice. To identify genes regulated by MafB, microarray proﬁl-
ing was performed on wild-type and MafB
/ pancreata at
embryonic day 18.5, with candidates evaluated by quantitative
RT-PCR and in situ hybridization. The potential role of MafA in
the expression of veriﬁed targets was next analyzed in adult
islets of a pancreas-wide MafA mutant (termed MafA
Panc).
RESULTS—MafB was produced in a larger fraction of -cells
than MafA during development and found to regulate potential
effectors of glucose sensing, hormone processing, vesicle forma-
tion, and insulin secretion. Notably, expression from many of
these genes was compromised in MafA
Panc islets, suggesting
that MafA is required to sustain expression in adults.
CONCLUSIONS—Our results provide insight into the sequen-
tial manner by which MafA and MafB regulate islet -cell
formation and maturation. Diabetes 59:2530–2539, 2010
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nsulin-secreting islet -cells play a pivotal role in the
regulation of fuel metabolism. Loss or dysfunction
of -cells causes an imbalance in glucose homeosta-
sis that leads to the development of diabetes. Efforts
aimed at understanding the molecular processes underly-
ing -cell development and function have provided per-
spectives into new diabetes treatment strategies. For
example, a hierarchy of transcription factors has been
found to regulate -cell differentiation during development
and adult islet cell function, a few of which are mutated in
type 2 diabetic patients as discussed by others (1–3). The
signiﬁcance of these proteins was recently reinforced
upon observing their expression during the stepwise dif-
ferentiation of human embryonic stem cells to -like cells
(4,5) and the reprogramming of adult acinar cells to -like
cells upon misexpression of a unique subset of transcrip-
tion factors, speciﬁcally MafA, Pdx1, and Ngn3 (6).
Among the transcription factors vital to the pancreas,
there are instances when members of the same gene
family contribute to -cell formation, including winged-
helix/forkhead (e.g., FoxA1/2) (7–9), NK6 homeodomain
(Nkx6.1 and Nkx6.2) (10–12), paired box homeodomain
(Pax4/6) (13–17), and basic leucine-zipper (MafA and
MafB) (18,19) proteins. FoxA1/2, Nkx6.1/6.2, and Pax4/6
are expressed broadly in pancreatic epithelial cells in both
islet hormone
 and hormone
 cells before or near the
onset of pancreatic morphogenesis (3) and then become
conﬁned to more speciﬁc cellular domains (e.g., Nkx6.1
[] and Pax6 [all islet cells]) or disappear entirely late in
development (Pax4, Nkx6.2). The large MafA/B factors are
distinct in being produced relatively later in development
and essentially only in hormone
 cells. Thus, MafB is
present in developing -(glucagon
) cells, -cells, and a
very small number of Ngn3
 islet hormone
 progenitors
and then becomes restricted to -cells soon after birth
(20,21). MafA is found exclusively in developing and adult
insulin
 cells, with expression ﬁrst detected at embryonic
day (E) 13.5 during the secondary and principal wave of
insulin
 cell production (22).
A comparison of the properties of islet-enriched tran-
scription factor mutant mice reveals a novel role for MafA
and MafB in -cell maturation and function. Thus, islet ,
, , ε, or pancreatic polypeptide producing cells are either
lost or respeciﬁed in most transcription factor knockout
mice (1–3), whereas the principal defect in MafB
/
embryos is reduced insulin and glucagon expression (18).
Furthermore, this change does not affect total endocrine
cell numbers, supporting a distinct importance in one or
more late steps in - and -cell differentiation (18). In
contrast, MafA is solely required for glucose-regulated
insulin secretion in adult islet -cells and is not involved in
islet cell development (19). Notably, MafB
 insulin
 cells
generated during human embryonic stem cell differentia-
tion were dysfunctional until becoming MafA
 insulin

(5), suggesting that the transition from MafB to MafA is
critical to -cell function.
To obtain a mechanistic understanding of the associa-
tion between MafB and MafA in -cell formation and
function, gene-proﬁling studies were performed with E18.5
pancreata from wild-type, MafB
/, MafA
Panc, and
MafA
Panc;MafB
/ embryos. (MafA
Panc mice were gen-
erated by crossing MafA
ﬂ/ﬂ mice with transgenic mice
producing Cre recombinase from the Pdx1
5.5 promoter
fragment early in development and in a pancreas-wide
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the MafB
/ mutant, but not in MafA
Panc mutant, consis-
tent with the much more critical role of MafB in - and
-cell development (18,21). Signiﬁcantly, MafB-dependent
genes were associated with adult -cell function, including
glucose sensing and insulin secretion. Interestingly, many
of these target genes were affected in a similar manner in
adult MafA
Panc islets, even though MafB was retained in
a fraction of the mutant insulin
 cell population. These
ﬁndings provide insight into why the -cell is dysfunc-
tional in MafA mutant mice, and they illustrate the unusual
interrelationship between closely related transcription fac-
tors in the generation of a particular islet cell type.
RESEARCH DESIGN AND METHODS
Animals. Pancreas-wide MafA deletion mutant mice were generated using the
Cre-loxP mediated recombination system. A conditional MafA allele was
generated using a targeting vector consisting of two loxP sites inserted into
the 5 (PstI site [699 bp] and 3 (KpnI site [1,658 bp]) end of the MafA exon
(supplementary Fig. 1A in the online appendix available at http://diabetes.
diabetesjournals.org/cgi/content/full/db10-0190/DC1). The herpes simplex vi-
rus-thymidine kinase (TK) gene was placed outside of the MafA gene
homology region for neomycin
R selection. After electroporation of 129S6-
derived mouse embryonic stem cells, 327 clones survived chemical selection.
Fifteen clones were correctly targeted, as determined by Southern blotting
hybridization. Two clones were independently injected in mouse blastocysts,
and then chimeric mice were bred with C57BL/6J mice for germline transmis-
sion screening. The FRT-ﬂanked neomycin
R gene was then removed in
transmitted MafA
ﬂ/ mice by crossing with FLPe mice (JAX human -actin
FLPe deleter strain; more information online at http://www.mmrrc.org/strains/
29994/029994.html). To delete MafA in the developing pancreas, MafA
ﬂ/ﬂ
animals were bred with Pdx1
5.5-Cre mice (a gift from Dr. Guoqiang Gu,
Vanderbilt University), which produce Cre recombinase by E10.5 in a pattern
analogous to endogenous Pdx-1 early in development (23, supplementary
reference 1). MafA
ﬂ/ﬂ;Pdx1
5.5-Cre mice were referred to as MafA
Panc, with
MafA effectively removed from the pancreas by E18.5 (Table 1, supplementary
Fig. 1B). MafB
/ mice were generated by homologous recombination (24).
For embryonic analysis, noon of the day of the vaginal plug discovery was
designated E0.5. The Vanderbilt University Institutional Animal Care and Use
Committee approved all of our studies in mice.
Microarray and quantitative RT-PCR analysis. E18.5 pancreas anlagen
from ﬁve independently derived wild-type MafA
Panc, MafB
/, and
MafA
Panc;MafB
/ mice were dissected in PBS and stored in RNAlater
(Ambion). Tissue RNA was isolated using the ToTALLY RNA isolation kit
(Ambion). RNA was further puriﬁed over RNeasy columns (Qiagen), and RNA
quality was analyzed using an Agilent 2100 Bioanalyzer. Each RNA sample
(100 ng) was ampliﬁed using the Ovation Aminoallyl RNA Ampliﬁcation and
Labeling System (NuGEN Technologies), and PancChip 6.1 (http://www.
betacell.org/ma, supplementary reference 2) microarray analysis was per-
formed at the Functional Genomics Core at the University of Pennsylvania.
Quantitative RT-PCR was conducted on total RNA from E18.5 pancreata or
12-week-old islets (n  3 for each genotype). The RNA (1 g) was transcribed
using iScript reverse transcriptase and iScript reaction mix (Bio-Rad). The
PCRs were performed using the SYBR Green (with dissociation curve)
program on an Applied Biosystems 7900 machine. All reactions were per-
formed in duplicate with reference dye normalization, and median cycling
threshold values were used for analysis. Primer sequences are available on
request.
Immunohistochemistry and in situ hybridization. Tissue ﬁxation, embed-
ding, and immunoﬂuorescence labeling were performed as previously de-
scribed (25). The primary antibodies used were guinea pig -insulin (1:2,000;
Linco Research), mouse -insulin (1:2,000; Invitrogen), guinea pig -glucagon
(1:2,000; Linco Research), sheep -somatostatin (1:2,000; American Research),
guinea pig -pancreatic polypeptide (1:2,000; Linco Research), rabbit -MafB
(1:10,000; Bethyl Laboratories), rabbit -MafA (1:1,000, Bethyl Laboratories),
rabbit -Slc30a8 (1:1,000, Mellitech), mouse -Rbp4 (1:1,000, Abnova), rabbit
-G6PC2 (1:500, a gift from Dr. John Hutton at the University of Colorado),
rabbit -Pdx1 (1:5,000, a gift from Dr. Chris Wright at Vanderbilt University),
mouse -Isl1 (1:300, Developmental Studies Hybridoma Bank), rabbit
-Nkx6.1 (1:1,000, Beta Cell Biology Consortium), and rabbit -Pax6 (1:200,
Covance Research Products). The secondary Cy2-, Cy3-, or Cy5-conjugated
donkey -rabbit, -guinea pig, and -sheep IgGs were obtained from Jackson
ImmunoResearch Laboratories. Nuclear counterstaining was performed using
YoPro1 or DAPI (Invitrogen). Immunoﬂuorescence images were acquired
using confocal microscopy (LSM510, Carl Zeiss).
In situ hybridization assays were performed using Neuronatin (base pair
119 to 1,163 relative to coding ATG) and Slc30a8 (base pair 166 to 1,269) gene
probes according to Henrique et al. (26). The Rbp4 cDNA plasmid (clone ID
IMAGp998P0711141Q1) was obtained from the resource center of the human
genome project (www.rzpd.de) and used to generate the probe (base pair
295–927).
Quantiﬁcation and statistical analysis. Immunolabeling for insulin and
MafA (or MafB) was performed on serial 6-m pancreatic sections that were
collected at 60-m (i.e., at E14.5), 84-m (E18.5), or 150-m (postnatal)
intervals. All insulin
 cells were imaged by confocal microscopy and pre-
sented as the percentage of MafA
insulin
 or MafB
insulin
 to total insulin

cells. At least 10 random ﬁelds were counted from wild-type and MafA
Panc
pancreata (n 	 3) to calculate the percentage of MafB
insulin
 cells in adult
islets. Immunolabeling for insulin, glucagon, somatostatin, and pancreatic
polypeptide-producing cells was performed on 12-week islet sections at
300-m intervals. At least 10 random ﬁelds were counted from wild-type and
MafA
Panc pancreata (n 	 4) to calculate the proportion of somatostatin

-cells within islets. Mean differences were tested for statistical signiﬁcance
using a two-tailed Student t test.
RESULTS
MafA and MafB are dynamically expressed in devel-
oping and adult -cells. There are two distinct waves of
insulin
 and glucagon
 cell production within the pancre-
atic epithelium during embryogenesis, with the massive
expansion of secondary transition cells starting at E13.5
populating the adult islet (27). Previous studies estab-
lished that MafB is expressed in both waves (18,21),
whereas MafA is only in the insulin
 cells of the second
wave (22). Quantitative immunohistochemical analysis
was performed at E15.5, E18.5, P14, and P28 to precisely
deﬁne the MafA and MafB expression pattern during
embryonic and postnatal -cell differentiation.
MafB was found in almost all insulin
 cells produced at
E14.5 and E18.5, whereas the fraction of MafA
 insulin

cells increased during this period (Fig. 1A). Our results are
in accordance with previous data showing that MafA was
expressed in only 54% of the insulin
 cells at E15.5 and
MafB in nearly 90% (21). However, MafB was present only
in very few insulin
 cells soon after birth (P14, 2.70 

0.11%) and was essentially absent in insulin
 cells after 4
weeks (P28, 0.69 
 0.06%). In contrast, MafA was detected
in most islet -cells by 4 weeks (Fig. 1A). The postnatal
switch in -cells from principally MafB to exclusively
MafA occurs during a period of cell maturation in regards
to islet architecture, islet cell mass, and glucose-sensitive
insulin secretion.
TABLE 1
The mRNA expression proﬁle of E18.5 wild-type and mutant
pancreata
% of wild-type
MafA
panc MafB
/ MafA
panc;MafB
/
MafA 1 
 1* 16 
 1* 2 
 1*
MafB 168 
 1* 10 
 6* 9 
 4*
Insulin 99 
 16 34 
 18* 11 
 3*
Glucagon 132 
 23 55 
 28* 31 
 10*
Isl1 112 
 12 118 
 50 117 
 42
Slc30a8 90 
 23 4 
 3* 0 
 0*
G6pc2 59 
 20* 18 
 9* 4 
 0*
Rbp4 84 
 21 196 
 54* 188 
 21*
Nnat 50 
 11* 31 
 7* 26 
 4*
Data are means 
 SEM. *Change from wild-type littermates is
signiﬁcant, P  0.05.
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Panc -
cells. MafB mRNA expression at E18.5 was elevated 1.7 

0.1-fold in MafA
Panc pancreata, yet no overt alterations in
islet hormone
 cell development or Isl1, Nkx6.1, Pax6, or
Pdx1 expression were found (supplementary Fig. 2). Also
similar to MafA
/ mice (19), changes in MafA
Panc -cell
function and islet morphology were ﬁrst observed postna-
tally (data not shown). Pan-endocrine Isl1 expression was
unaffected in the MafA
Panc, MafA
Panc;MafB
/, and
MafB
/ mutants at E18.5 (Table 1), supporting evidence
linking MafB to - and -cell maturation, but not islet cell
formation or viability (18,21). As expected, insulin mRNA
levels were compromised in MafB
/ (18) and MafA
Panc;
MafB
/ samples from E18.5, but not the MafA
Panc
(Table 1) or MafA
/ mutants (19). The larger effect on
Insulin mRNA expression in MafA
Panc;MafB
/ pan-
creata implies that MafA contribution to embryonic
Insulin transcription becomes signiﬁcant only in the
absence of MafB. This was also indicated by the delay in
residual insulin
 cell production until the beginning of
the secondary transition at E13.5 in MafB
/ mice (18).
Strikingly, immunohistochemical analyses revealed that
MafB protein expression was retained in a fraction of
insulin
 cells in adult MafA
Panc mice (compare Fig. 1B
with C; 33.4 
 5.6% of insulin
 cells express MafB). These
results showed that the MafB protein produced in adult
MafA
Panc -cells does not compensate for the loss of
MafA.
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FIG. 1. MafA and MafB expression is dynamically regulated in developing and adult -cells. A: The percentage of -cells coexpressing MafA or
MafB was assessed at E14.5, E18.5, P14, and P28 by quantiﬁcation of the number of insulin
 cells costaining with either MafA or MafB. Sections
spanning the entire pancreas of wild-type mice were used; the results are presented as the mean  SEM. B and C: MafB is sustained in a fraction
of the insulin
 cells in MafA
panc islets. Wild-type (B) and mutant (C) pancreatic sections were stained for MafB (green) and insulin (red).
Notably, MafB
 is not found in wild-type insulin
 cells, but is found in MafA
Panc. Yellow arrowhead denotes representative MafB
 insulin
 cells,
and white arrowhead denotes MafB
 insulin
 cells. Nuclei were stained with YO-PRO-1 in blue. MafB was found in 33.4  5.6% of MafA
panc
insulin
 cells (n  3). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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-cell function during embryogenesis. Gene expres-
sion proﬁling studies of E18.5 wild-type, MafA
Panc,
MafB
/, and MafA
Panc;MafB
/ pancreata were per-
formed to more broadly deﬁne the regulatory roles of
MafB and MafA in -cell differentiation. Thirty-ﬁve
genes with mRNA levels altered by 1.5-fold (P  0.01,
false discovery rate 25%) were identiﬁed using the
PancChip 6 microarray platform in the MafB
/ mutant,
and 47 were identiﬁed in MafA
Panc;MafB
/ (supple-
mentary Table 1). The proﬁles were similar between
MafB
/ and MafA
Panc;MafB
/ (29 genes were differ-
entially expressed in both genotypes), with most
changes more pronounced in MafA
Panc;MafB
/ (sup-
plementary Table 1). In contrast, no differences were
found between MafA
Panc and the wild-type gene ex-
pression proﬁle.
Gene ontology analysis revealed that the differentially
expressed genes were mainly involved in aspects of ma-
ture -cell function, such as ion binding and transport,
signal transduction, and hormone secretion (supplemen-
tary Table 2). The mRNA changes of many candidate genes
(like Slc30a8, G6pc2, Rbp4, Nnat, Insulin, and Slc2a2)
were independently veriﬁed in E18.5 MafB
/ and
MafA
Panc;MafB
/ pancreata by quantitative RT-PCR
(Table 1; data not shown). The studies described below
examined the signiﬁcance of MafA in adult expression of
genes initially regulated by MafB. Expression within spe-
ciﬁc islet cell types was examined by in situ hybridization
during development and by immunohistochemistry in
adults; unfortunately, limitations in the technique (e.g., in
situ) or protein abundance precluded examination of these
temporal periods using both methods. Importantly, our
results provide mechanistic insight into the mutually ben-
eﬁcial relationship between MafB and MafA and provide
an explanation for why -cell activity decreases in
MafA
/ and MafA
Panc mice.
MafB activates Slc30a8-encoded zinc transporter ex-
pression in developing - and -cells, whereas MafA
is essential in adult -cells. Slc30a8 or ZnT8 encodes
an islet-speciﬁc zinc transporter that facilitates the accu-
mulation of zinc from the cytoplasm into intracellular
vesicles for insulin maturation and storage (28,29). Over-
expression of Slc30a8 enhances glucose-stimulated insulin
secretion in INS1 -cells (29), whereas variants in this
locus are linked to type 2 diabetes in humans (30,31). The
transporter is also a type 1 diabetes autoantigen in humans
(32).
The normal Slc30a8 expression pattern during pan-
creatic development was ﬁrst determined by in situ
hybridization. Slc30a8 mRNA transcripts were found in
both developing - and -cells (Fig. 2A–D, supplemen-
tary Fig. 3). Notably, Slc30a8 expression was lost in -
cells at E18.5 in the MafB
/ mutant, but retained in the
remaining insulin
 cells (Fig. 2E and F, supplementary
Fig. 3). Signiﬁcantly, Slc30a8 expression was undetect-
able in the MafA
Panc;MafB
/ mutant (Fig. 2G and H,
supplementary Fig. 3), demonstrating that expression
was mediated by MafA in the residual insulin
 cells in
the MafB mutants. These results suggest that MafB is
the primary activator of Slc30a8 expression in - and
-cells during development.
Next, immunohistochemical staining was performed to
assess Slc30a8 expression in adult wild-type and
MafA
Panc islets. As reported while this work was in
progress (33), Slc30a8 is present in both - and -cells
(Fig. 2J and K). (The speciﬁcity of the Slc30a8 antibody
was conﬁrmed upon comparing pancreatic samples from
wild-type and Slc30a8
/ mice [supplementary Fig. 4]).
Expression was essentially absent in 3-month-old islet
insulin
 cells from the MafA
Panc mutant (Fig. 2L). The
remaining Slc30a8 in MafA
Panc islets is primarily (if not
exclusively) in -cells (Fig. 2M). These data imply that
MafA and MafB function at distinct temporal stages to
promote Slc30a8 expression in -cells.
Both MafA and MafB activate islet-speciﬁc glucose-
6-phosphatase catalytic subunit-2 protein expres-
sion. Glucose-6-phosphatase catalytic subunit-2 protein
(G6pc2, also known as IGRP) is a major autoantigen in
type 1 diabetes (34) and may regulate fasting plasma
glucose levels in humans (35). Expression of G6pc2 mRNA
was signiﬁcantly compromised in E18.5 pancreata from
MafB
/, MafA
Panc;MafB
/, and MafA
Panc embryos.
However, the impact of MafA appears greater in adult
MafA
Panc islets than during development (see Fig. 3A and
Table 1), as a much lower level of G6pc2 was present in
3-month-old MafA
Panc islet -cells than wild-type (Fig. 3,
compare D with G). These data indicate that both MafA
and MafB play a role in G6pc2 expression and complement
recent cell-line–based studies showing that MafA stimu-
lates G6pc2 transcription by binding to the 177/164 bp
element in its promoter region (36).
Neuronatin expression is principally regulated by
MafB. Neuronatin (Nnat) is involved in modulating ion
channel activity in -cells, with overexpression increasing
insulin secretion by elevating intracellular Ca
2 levels
(37,38). In situ hybridization analysis showed that Nnat
mRNA was expressed at E15.5 and E18.5 in insulin
 cells
and in a population that was neither insulin
 nor gluca-
gon
 (Fig. 4, see WT panel, supplementary Figs. 5 and 6).
Nnat synthesis was predominately in insulin
 cells by
E18.5. A profound reduction in steady-state Nnat levels
was observed in E18.5 MafB
/ and MafA
Panc;MafB
/
pancreata (Table 1), with the enduring Nnat detected only
in the remaining mutant insulin
 cells (Fig. 4, supplemen-
tary Figs. 5 and 6).
These results suggest that Nnat expression in develop-
ing -cells is only partially dependent on MafB. This was
also true of Pdx1 transcription wherein the 50% reduc-
tion in E18.5 mRNA levels reﬂected the loss in the
MafB
/ insulin
 cell population (18). Notably, steady-
state Nnat (Fig. 4M) and Pdx1 (19) levels were unchanged
in MafA
Panc adult islets, a distinction from Slc30a8 (Fig.
2I)o rG6pc2 (Fig. 3A). These data demonstrate that only
MafB regulates Nnat expression.
Rbp4 expression is upregulated in E18.5 MafB mu-
tant and MafA
Panc adult islets. Rbp4 contributes to
the pathogenesis of type 2 diabetes, as its release from
adipocytes causes systemic insulin resistance in both mice
and humans (39). This circulating protein is also produced
in the liver, although little was known about its effect on
islets until recently. Rbp4 has now been found to repress
glucose-stimulated insulin secretion in both isolated rat islets
and in vivo (P. Fueger, C. Newgard, unpublished data).
In distinction to the genes described previously, Rbp4
mRNA expression was increased in MafB
/ and
MafA
Panc;MafB
/ pancreata at E18.5 (Table 1). In situ
RNA analysis was performed to determine the distribution
of Rbp4 in hormone
 cells during development. Rbp4
transcripts were found in the majority of wild-type insu-
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FIG. 2. Islet zinc transporter Slc30a8 expression is activated by MafB during embryogenesis and by MafA in islet -cells. Slc30a8 transcripts
(green) were detected by in situ analysis in wild-type insulin
 (red, A and C) and glucagon
 (red, B and D) cells at E15.5 and E18.5. Expression
is still detected in the remaining insulin
 cells (E), but lost in glucagon
 (F) cells in MafB
/ pancreata. No Slc30a8 expression was detected
in the MafA and MafB compound mutant (MafA
Panc; MafB
/; G and H). I: RT-PCR data illustrate the change in Slc30a8 mRNA expression
between 3-month-old MafA
panc and wild-type islets. *P < 0.05 (n  3). Slc30a8 was detected in islet -cells (J) and -cells (K) of 12-week-old
wild-type islets by immunoﬂuorescence. Expression was profoundly reduced in MafA
Panc -cells (L) and unaffected in -cells (M). The (L)
Slc30a8
 insulin
 cells labeled with white arrows correspond to (M) Slc30a8
 glucagon
 cells denoted by yellow arrows. Scale bar  20 m.
Nuclei were stained in blue in panels J–M. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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 and glucagon
 cells at E15.5, but only in a small
portion of insulin
, glucagon
, and somatostatin
 () cells
by E18.5 (Fig. 5, WT panel, supplementary Figs. 7 and 8).
In contrast, most of the remaining hormone
 cell types, as
well as hormone
 islet cells, synthesize Rbp4 in the
MafB
/ and MafA
Panc;MafB
/ mutants (Fig. 5C–F,
J–O, supplementary Figs. 7 and 8).
Quantitative RNA analysis demonstrated that adult
MafA
Panc islets contained elevated Rbp4 mRNA levels (Fig.
5P). Notably, Rbp4 protein expression was detected only in
somatostatin-producing -cells in both wild-type and
MafA
Panc islets (Fig. 5Q–X). However, there was no change
from the wild-type in the somatostatin
 -cell proportion
produced in mutant islets (wild-type: 8.94 
 0.73% vs.
MafA
Panc: 8.59 
 0.89%). Collectively, the data indicate that
MafA and MafB negatively regulate production of this effec-
tor of insulin secretion and insulin resistance in developing
and mature islet cell types.
DISCUSSION
The expression pattern and functional characteristics of
MafA and MafB is unusual when compared with all other
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FIG. 3. G6pc2 expression is compromised in adult islets lacking MafA. A: Quantitative RT-PCR analysis revealed that G6pc2 mRNA levels were
signiﬁcantly downregulated in adult MafA
Panc islets. *P < 0.05 (n  3). G6pc2 expression (green) in islet insulin
 cells (B–D)( red) was shown
by immunostaining to be profoundly reduced in MafA
panc islets (E–G). Scale bar  20 m. Nuclei were stained with YO-PRO-1 (blue). (A
high-quality digital representation of this ﬁgure is available in the online issue.)
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/ mutant
affects only adult islet architecture and -cell activity,
whereas MafB and essentially all other pancreatic transcrip-
tional regulators (at least) affect islet cell development. Here
we have examined the relationship between these closely
related factors in islet -cell formation and function, an
especially important issue considering that MafB is not
produced within this islet cell population in adults.
Histologic and gene expression analyses of regulated
genes identiﬁed from a microarray screen performed on
E18.5 MafB
/, MafA
Panc;MafB
/, and MafA
Panc pan-
creata clearly illustrated that MafB is a more potent
regulator of -cell development than MafA, with the ma-
jority of differentially expressed genes identical in
MafB
/ and MafA
Panc;MafB
/ samples. Our data also
indicate that MafB may serve in a compensatory capacity
in the embryonic MafA
Panc mutant, since MafB levels
were ampliﬁed at E18.5. Notably, persistent MafB expres-
sion in a fraction of adult MafA
Panc -cells did not
prevent the change in islet architecture and -cell function
ﬁrst described in MafA
/ mice (19). MafB may not
compensate in this setting because of limiting protein
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FIG. 4. Nnat expression in -cells is regulated only by
MafB. Appreciable levels of Nnat (green) were detected in
insulin
 (red, A, yellow arrows), insulin
 (A, white ar-
rows), but not glucagon
 (red, B) cells by in situ analysis.
Nnat was essentially restricted to -cells by E18.5 in the
wild-type (G and H) and the remaining insulin
 cells in the
MafB
/ and MafA
Panc;MafB
/ mutants (I and L). Scale
bar  20 m. Nnat expression was unaffected in MafA
panc
islets (M). Yellow arrows denote Nnat
hormone
 cells
and white arrows denote Nnat
hormone
 cells. (A high-
quality digital representation of this ﬁgure is available in
the online issue.)
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/ and islet MafA
Panc mutants. Rbp4 transcripts (green) are present in some (A and G) insulin

(red, yellow arrows) and (B and H) glucagon
 (red) cells (A and B, yellow arrows) at both E15.5 and E18.5, with expression also found in (I)
somatostatin
 	-cells (red, yellow arrows) by E18.5. The number of hormone
 Rbp4
 cells increased in MafB
/ and MafA
Panc;MafB
/ mutant
pancreata (C–F; J–O). P: Rbp4 mRNA expression was elevated in 12-week MafA
Panc islets. S–X: The Rbp4 protein is found in somatostatin
(SST)
 	-cells in (S) wild-type and (W) MafA
Panc islets, and not (Q and U) insulin
,( R and V) glucagon
,o r( T and X) pancreatic peptide
 cells.
Scale bar  20 m. Nuclei were stained in blue in panels Q–W. White arrows denote Rbp4
 hormone
 cells. (A high-quality digital representation
of this ﬁgure is available in the online issue.)
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activation properties with MafA. In this regard, it is
noteworthy that MafA was found to activate Insulin
expression, whereas MafB speciﬁcally stimulated gluca-
gon in experiments performed in endocrine cells
(20,22,40).
Expression proﬁling analysis showed that MafB acti-
vates genes involved in mature endocrine function, includ-
ing those signiﬁcant to glucose sensing (e.g., Slc2a2),
vesicle maturation (Slc30a8), Ca
2 signaling (Camk2b),
and insulin secretion (Nnat) (Table 1, supplementary
Table 2; data not shown). In contrast, the levels of
transcription factors associated with -cell differentiation
(e.g., Pax6, NeuroD1, Pax4, and Isl1) were unaffected in
the MafB
/ (or MafA
Panc;MafB
/) mutant, supporting
a role for MafB in late events essential to cell maturation
and not early islet cell speciﬁcation (e.g., Ngn3) or cell
lineage commitment steps (e.g., Arx, Isl1, Nkx2.2, Pax4,
and Pax6) (18). This proposal is also supported by the fact
that MafB
/ mutant retained the expression of some -
and -cell–enriched developmental markers while under-
going a loss in insulin and glucagon production (18).
Interestingly, proﬁling E18.5 MafB
/ or MafA
Panc;
MafB
/ pancreata did not pick up the Gck (i.e., glucoki-
nase), Pcsk1,o rGlp1R products that were previously
associated with MafA control in a candidate gene study
performed with INS1 -cells (41). These genes may be
preferentially under later stage MafA control, since, for
example, Gck is produced in high levels postnatally only in
-cells (42).
Strikingly, our results demonstrate that islet MafA con-
trols many genes ﬁrst regulated by MafB in developing -
cells. This conclusion is based on immunohistological and
mRNA analysis of selected MafB
/ microarray candidate
genes within the embryonic MafB
/ pancreas and adult
MafA
Panc islet. For example, Slc30a8 expression was
compromised in MafB mutant glucagon
 and insulin

cells during development and speciﬁcally in adult MafA
mutant insulin
 cells (Fig. 2). Instances were also found
when MafB was the primary (if not exclusive) activator,
such as Nnat (Fig. 3) and Pdx1 (data not shown).
Given the signiﬁcance of MafA and MafB mutual target
genes (e.g., Slc30a8, Insulin, and Slc2a2)t o-cell func-
tion, insulin secretion defects associated with the MafA
/
(19) and MafA
Panc mutants would be expected. The
recent studies showing that Rbp4 produced from rat islet
cells inhibits glucose-stimulated insulin secretion (P. Fu-
eger, C. Newgard, unpublished data) suggests that activa-
tion in -cells of MafA
Panc mouse would also act to
diminish -cell function. (Rbp4 is also principally ex-
pressed in human islet -cells [supplementary Fig. 9]).
Rbp4 attenuates insulin-induced phosphorylation of insu-
lin receptor substrate-1 in human adipocytes (supplemen-
tary reference 3). Presumably, it also inhibits insulin-
responsive signalling that is essential to -cell function
(supplementary reference 4). We believe that the in-
creased Rbp4 expression in -cells is a byproduct of
MafA
Panc -cell inactivity. Further investigation may re-
veal that islet Rbp4 expression is also induced in mouse
models of type 2 diabetes wherein islet MafA expression
was selectively lost (43,44).
Although other closely related transcription factors are
synthesized within the pancreas (e.g., Pax4/Pax6, Nkx6.1/
Nkx6.2, FoxA1/FoxA2), none act as speciﬁcally and in
such a coordinated manner to affect islet cell function as
MafA and MafB. For instance, Nkx6.1 and Nkx6.2 are
expressed more broadly and earlier, with only Nkx6.1
signiﬁcantly inﬂuencing -cell development and function
(10,12,45). Likewise, FoxA1 and FoxA2 have a similar
early expression pattern to Nkx6.1/6.2 in the forming
pancreas, with the dominant and general role in islet cell
formation and function served by FoxA2 (7–9). Perhaps
parallels can be made between islet MafA and MafB and
the basic helix-loop-helix Myf-5, MyoD, and Myogenin
factors through their actions in skeletal muscle formation.
Hence, gene knockout experiments in mice have shown
that myogenin plays an essential role in the late differen-
tiation of myoblasts to myotubes (46) (analogous to MafA
in the maturing -cell), whereas both Myf-5 and MyoD act
upstream and are critical to myoblast formation (47)
(acting similarly to MafB). However, expression of any of
these myogenic factors can convert a variety of tissue
culture cells into muscle cells (48,49), whereas only MafA
appears capable of activating Insulin transcription in vitro
(22,40). Interestingly, differences in myogenic potential
was revealed when Myogenin was expressed from the
Myf5 locus in vivo (48), suggesting that a knock-in analy-
sis might also reveal elementary regulatory differences
between the MafA and MafB proteins.
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